2021.05.10 17:21Nation

武田、モデルナワクチンの治験データを提出　抗体の増加確認

　武田薬品工業は１０日、米バイオ医薬品企業モデルナが開発した新型コロナワクチンの国内治験データについて、審査を行う医薬品医療機器総合機構（ＰＭＤＡ）に提出したと発表した。接種した全員で抗体の増加が確認できたという。（2021/05/10-17:21）

英文版に切り替え

2021.05.10 17:21Nation

Takeda Submits Trial Data on Moderna's COVID-19 Vaccine

Twitter

Facebook

LINE

Takeda Pharmaceutical Co. said Monday that it has submitted data on its trial in Japan of U.S. biotechnology startup Moderna Inc.'s COVID-19 vaccine to the Pharmaceuticals and Medical Devices Agency, which is screening the application for approval of the vaccine in Japan.
   The Japanese drugmaker said that antibody increases have been confirmed in all participants of the domestic vaccine trial.
   Takeda launched the domestic trial with 200 participants in January and filed the vaccine application in March.
   The Japanese government has a contract to receive 50 million doses of the Moderna vaccine. It plans to use the vaccine at mass vaccination venues to be opened as early as this month.

Switch to Japanese